Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 19;16(1):318.
doi: 10.1186/s13023-021-01956-5.

Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment

Margaux Poleur  1 , Ana Ulinici  1 , Aurore Daron  1 , Olivier Schneider  1 , Fabian Dal Farra  1 , Marie Demonceau  1 , Mélanie Annoussamy  2 , David Vissière  2 , Damien Eggenspieler  2 , Laurent Servais  3   4
Affiliations

Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment

Margaux Poleur et al. Orphanet J Rare Dis. .

Abstract

Background: Normative data are necessary for validation of new outcome measures. Recently, the 95th centile of stride speed was qualified by the European Medicines Agency as a valid secondary outcome for clinical trials in subjects with Duchenne muscular dystrophy. This study aims to obtain normative data on spontaneous stride velocity and length in a non-controlled environment and their evolution after 12 months.

Method: Ninety-one healthy volunteers (50 females, 41 males), with a mean age of 16 years and 2 months, were recruited and assessed at baseline and 12 months later. The 4-stair climb, 6-min walk test, 10-m walk test and rise from floor assessments were performed. Stride length, stride velocity, and the distance walked per hour were studied in an everyday setting for one month after each evaluation.

Results: Of the 91 subjects assessed, 82 provided more than 50 h of recordings at baseline; and 73 subjects provided the same at the end of the year. We observed significant positive correlations of the stride length with age and height of participants, and a significant increase of the median stride length in children after the period. In this group, the 95th centile stride velocity was not correlated with age and was stable after one year. All measures but the 10MWT were stable in adults after a one-year period.

Conclusion: This study provides with data on the influence of age, height, and gender on stride velocity and length as well as accounting for natural changes after one year in controls.

Keywords: Accelerometer; Healthy volunteers; Home monitoring; Stride length; Stride velocity.

PubMed Disclaimer

Conflict of interest statement

Academic authors declare no competing interests. Melanie Annoussamy and Damien Eggenspieler are employed by Synsav, the medium-sized enterprise responsible for ActiMyo® development. David Vissière is the CEO, founder and main shareholder of Sysnav.

Figures

Fig. 1
Fig. 1
Flow-chart displaying the compliance and inclusion of subjects. Withdrawals resulted from loss of follow up (5 subjects) and withdrawal by the subject (2 subjects)
Fig. 2
Fig. 2
One year evolution of SV50C (A), SV95C (B), SL50C (C) and SL95C (D) in subjects aged 5 to 17 years. SV50C 50th centile stride velocity; SV95C 95th centile stride velocity; SL50C 50th centile stride length; SL95C 95th centile stride length
See this image and copyright information in PMC

References

    1. Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79. doi: 10.1186/s13023-017-0631-3. - DOI - PMC - PubMed
    1. Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014;24(6):482–491. doi: 10.1016/j.nmd.2014.03.008. - DOI - PubMed
    1. Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, et al. Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 2020;77(8):982–991. doi: 10.1001/jamaneurol.2020.1264. - DOI - PMC - PubMed
    1. Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020;94(21):e2270–e2282. doi: 10.1212/wnl.0000000000009233. - DOI - PMC - PubMed
    1. McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10101):1489–1498. doi: 10.1016/s0140-6736(17)31611-2. - DOI - PubMed

Publication types